Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.59 |
| ▸ | PPARG | P37231 | 8/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.59 |
| ▸ | OXER1 | Q8TDS5 | 5/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | RXRA | P19793 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 7/20 | 0.47 |
| ▸ | F3 | P13726 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646061 | 0.90 | ALDH1A1 (0.62) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL16418076 | 0.90 | ALDH1A1 (0.62) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL23646060 | 0.90 | ALDH1A1 (0.76) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL23646062 | 0.90 | ALDH1A1 (0.76) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL23646056 | 0.90 | ALDH1A1 (0.76) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL23646058 | 0.90 | ALDH1A1 (0.76) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL7675737 | 0.87 | ALDH1A1 (0.64) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL31651474 | 0.87 | ALDH1A1 (0.64) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL12512898 | 0.83 | NFKB1 (0.60) | ALDH1A1PPARGCYP19A1OXER1FFAR1 | |
| SCHEMBL23646064 | 0.80 | ALDH1A1 (0.77) | ALDH1A1PPARGCYP19A1OXER1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | claimed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| US-20250199014-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | claimed |
| US-12188948-B2 | Metabolite biomarkers for diseases associated with the contact activation system | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| WO-2024200855-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2024-10-03 | — | — | WO | claimed |
| EP-4437858-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2024-10-02 | — | — | EP | claimed |
| CN-118714935-A | Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment | 阿马里纳药物爱尔兰有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-117169508-A | Metabolite biomarkers for diseases associated with contact activation systems | 武田药品工业株式会社 | 2023-12-05 | — | — | CN | claimed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| CN-109716137-B | Metabolite biomarkers for diseases associated with contact activation systems | 武田药品工业株式会社 | 2023-07-21 | — | — | CN | claimed |
| US-20220365101-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-17 | — | — | US | claimed |
| US-11340237-B2 | Metabolite biomarkers for diseases associated with the contact activation system | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-24 | — | — | US | claimed |
| US-20190361036-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | DYAX CORP. (US) | 2019-11-28 | — | — | US | claimed |
| EP-3513197-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | Dyax Corp. (US) | 2019-07-24 | — | — | EP | claimed |
| WO-2018053247-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | DYAX CORP. (US) | 2018-03-22 | — | — | WO | claimed |
| WO-2026107250-A1 | METHODS AND SYSTEMS FOR PROFILING FATTY LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3513197-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | Dyax Corp. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053247-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | DYAX CORP. (US) | 2018-03-22 | — | — | WO | disclosed |